Literature DB >> 22697477

Treatment of ovarian hyperstimulation syndrome using gonadotropin releasing hormone antagonist: a pilot study.

Marzieh Agha Hosseini1, Atossa Mahdavi, Ashraf Aleyasin, Leili Safdarian, Fatemeh Bahmaee.   

Abstract

OBJECTIVE: This novel study describes an effective outpatient treatment for ovarian hyperstimulation syndrome (OHSS) that results in rapid normalization of symptoms. STUDY
DESIGN: A total of twenty-seven infertile women undergoing assisted reproductive technique with early-onset OHSS were enrolled in this non-randomized clinical trial in an academic infertility center. In all patients, after complete desensitization with long-term protocol ovarian stimulation with gonadotropins was commenced. Final oocyte maturation was triggered with human chorionic gonadotrophin. Oocytes were collected 36-38 h later using transvaginal-guided follicle aspiration under general anaesthesia. All embryos were frozen and study group patients received two consecutive doses of GnRH antagonist (Cetrotide) and the control group received daily dose of cabergoline for a week.
RESULTS: The research revealed that moderate and severe OHSS, hospitalization or acute care for OHSS and ascites tap were significantly lower in the antagonist (Cetrotide) group. The Patients' satisfaction with Cetrotide was noticeable. No side effect was reported in either group.
CONCLUSION: GnRH antagonists seem to be an effective outpatient treatment with rapid onset activity and minimal side effects for the management of early OHSS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22697477     DOI: 10.3109/09513590.2012.683076

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  4 in total

1.  Cetrotide administration in the early luteal phase in patients at high risk of ovarian hyperstimulation syndrome: A controlled clinical study.

Authors:  Ya-Qin Wang; Nan Yu; Wang-Min Xu; Qin-Zhen Xie; Wen-Jie Yan; Geng-Xiang Wu; Jing Yang
Journal:  Exp Ther Med       Date:  2014-10-06       Impact factor: 2.447

2.  Sequential E2 levels not ovarian maximal diameter estimates were correlated with outcome of cetrotide therapy for management of women at high-risk of ovarian hyperstimulation syndrome: a randomized controlled study.

Authors:  Khalid M Salama; Hesham M Abo Ragab; Mohammed F El Sherbiny; Ali A Morsi; Ibrahim I Souidan
Journal:  BMC Womens Health       Date:  2017-11-13       Impact factor: 2.809

Review 3.  The use of gonadotropin-releasing hormone antagonist post-ovulation trigger in ovarian hyperstimulation syndrome.

Authors:  Neil Chappell; William E Gibbons
Journal:  Clin Exp Reprod Med       Date:  2017-06-30

4.  Gonadotropin releasing hormone antagonist administration for treatment of early type severe ovarian hyperstimulation syndrome: a case series.

Authors:  Dayong Lee; Se Jeong Kim; Yeon Hee Hong; Seul Ki Kim; Byung Chul Jee
Journal:  Obstet Gynecol Sci       Date:  2017-09-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.